Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01550003 · ClinicalTrials.gov registry record · Phase 3
Pediatric Arthritis Study of Certolizumab Pegol
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT01550003 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 193 participants.
The verdict
NCT01550003, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Interventions
- DRUG Certolizumab Pegol (CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2012-03-08 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01550003
The ClinicalTrials.gov registry entry for NCT01550003 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol (CZP) is the first listed.
NCT01550003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01550003 about?
NCT01550003 is a clinical study titled "Pediatric Arthritis Study of Certolizumab Pegol". A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
What is the current status of trial NCT01550003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2012-03-08. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT01550003?
The interventions under investigation include: Certolizumab Pegol (CZP) (DRUG).
Who is sponsoring clinical trial NCT01550003?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.